Information provided by the nominee

Last year was very successful for MidEuropa, which saw it return c.€1bn to investors, through full exits of Diagnostyka and Profi, partial exits of Mlinar and M+, and ABB of Allegro. In 2024, the firm also invested in Famar, a leading pharmaceutical contract development and manufacturing organisation and continued to grow its portfolio using add-on acquisitions and operational expertise.